[1] Brauer F, Castillo-Chavez C. Mathematical Models in Population Biology and Epidemiology. Springer, New York; 2012. (Texts Appl Math; 40). doi:10.1007/978-1-4614-1686-9.
[2] Brauer F, van den Driessche P, Wu J, Morel J-M, Takens F, Teissier B, eds. Mathematical Epidemiology. Springer, Berlin; 2008. (Lecture Notes Math; 1945). doi:10.1007/978-3-540-78911-6.
[3] Kermack WO, McKendrick AG. A contribution to the mathematical theory of epidemics. Proc R Soc Lond A. 1927;115(772):700–21. doi:10.1098/rspa.1927.0118.
[4] Busenberg SN, Hadeler KP. Demography and epidemics. Math Biosci. 1990;101(1):63–74.
[5] Busenberg S, van den Driessche P. Analysis of a disease transmission model in a population with varying size. J Math Biol. 1990;28(3):257–70. doi:10.1007/BF00178776.
[6] Derrick WR, van den Driessche P. A disease transmission model in a nonconstant population. J Math Biol. 1993;31(5):495–512. doi:10.1007/BF00173889.
[7] Martcheva M, Castillo-Chavez C. Diseases with chronic stage in a population with varying size. Math Biosci. 2003;182(1):1–25.
[8] Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford University Press, Oxford; 1991.
[9] Chayoukh O, Zakary O. Transferring control strategies in epidemiological models using τ-equivalences. Commun Math Biol Neurosci. 2025;2025:54.
[10] Sharomi O, Malik T. Optimal control in epidemiology. Ann Oper Res. 2017;251(1):55–71. doi:10.1007/s10479-015-1834-4.
[11] Klamka J. Controllability of dynamical systems: a survey. Bull Pol Acad Sci Tech Sci. 2013;61(2):335–42.
[12] Sussmann HJ, Jurdjevic V. Controllability of nonlinear systems. J Differ Equ. 1972;12(1):95–116.
[13] Jung E, Lenhart S, Feng Z. Optimal control of treatments in a two-strain tuberculosis model. Discrete Contin Dyn Syst B. 2002;2(4):473–82. doi:10.3934/dcdsb.2002.2.473.
[14] Moualeu DP, Weiser M, Ehrig R, Deuflhard P. Optimal control for a tuberculosis model with undetected cases in Cameroon. Commun Nonlinear Sci Numer Simul. 2015;20(3):986–1003.
[15] Silva CJ, Torres DFM. Optimal control for a tuberculosis model with reinfection and post-exposure interventions. Math Biosci. 2013;244(2):154–64.
[16] Agusto FB, Adekunle AI. Optimal control of a two-strain tuberculosis–HIV/AIDS co-infection model. Biosystems. 2014;119:20–44.
[17] Whang S, Choi S, Jung E. A dynamic model for tuberculosis transmission and optimal treatment strategies in South Korea. J Theor Biol. 2011;279(1):120–31.
[18] Kim BN, Nah K, Chu C, Ryu SU, Kang YH, Kim Y. Optimal control strategy of Plasmodium vivax malaria transmission in Korea. Osong Public Health Res Perspect. 2012;3(3):128.
[19] Prosper O, Ruktanonchai N, Martcheva M. Optimal vaccination and bednet maintenance for the control of malaria in a region with naturally acquired immunity. J Theor Biol. 2014;353:142–56.
[20] Joshi HR. Optimal control of an HIV immunology model. Optim Control Appl Methods. 2002;23(4):199–213. doi:10.1002/oca.710.
[21] Fister KR, Lenhart S, McNally JS. Optimizing chemotherapy in an HIV model. Electron J Differ Equ. 1998.
[22] Yang Y, Xiao Y, Wu J. Pulse HIV vaccination: feasibility for virus eradication and optimal vaccination schedule. Bull Math Biol. 2013;75(5):725–51.
[23] Kwon HD, Lee J, Yang SD. Optimal control of an age-structured model of HIV infection. Appl Math Comput. 2012;219(5):2766–79.
[24] Roshanfekr M, Farahi MH, Rahbarian R. A different approach of optimal control on an HIV immunology model. Ain Shams Eng J. 2014;5(1):213–19.
[25] Zhou Y, Liang Y, Wu J. An optimal strategy for HIV multitherapy. J Comput Appl Math. 2014;263:326–37.
[26] Adams BM, Banks HT, Davidian M, Kwon HD, Tran HT, Wynne SN, et al. HIV dynamics: modeling, data analysis, and optimal treatment protocols. J Comput Appl Math. 2005;184(1):10–49. doi:10.1016/j.cam.2005.02.002.
[27] Costanza V, Rivadeneira PS, Biafore FL, D’Attellis CE. Optimizing thymic recovery in HIV patients through multidrug therapies. Biomed Signal Process Control. 2013;8(1):90–97.
[28] Zakary O, Rachik M, Elmouki I. On the impact of awareness programs in HIV/AIDS prevention: an SIR model with optimal control. Int J Comput Appl. 2016;133(9):1–6.
[29] Rong L, Perelson AS. Treatment of hepatitis C virus infection with interferon and small-molecule direct antivirals: viral kinetics and modeling. Crit Rev Immunol. 2010;30(2):131–48.
[30] Zakary O, Rachik M, Elmouki I. On effectiveness of an optimal antiviral bitherapy in HBV-HDV coinfection model. Int J Comput Appl. 2015;127(12):1–10.
[31] Agusto FB. Optimal isolation control strategies and cost-effectiveness analysis of a two-strain avian influenza model. Biosystems. 2013;113(3):155–64.
[32] Yan X, Zou Y. Optimal and sub-optimal quarantine and isolation control in SARS epidemics. Math Comput Model. 2007;47(1–2):235–45.
[33] Li Y. Optimal control for an epidemic model of COVID-19 with time-varying parameters. Mathematics. 2024;12(10):1484.
[34] Seddighi Chaharborj S, Seddighi Chaharborj S, Hassanzadeh Asl J, Phang PS. Controlling of pandemic COVID-19 using optimal control theory. Results Phys. 2021;26:104311.
[35] Pontryagin LS. Mathematical Theory of Optimal Processes. CRC Press, Boca Raton; 1987.
[36] Bolzoni L, Bonacini E, Soresina C, Groppi M. Time-optimal control strategies in SIR epidemic models. Math Biosci. 2017;292:86–96.
[37] Grigorieva EV, Khailov EN, Korobeinikov A. Optimal control for a SIR epidemic model with nonlinear incidence rate. Math Model Nat Phenom. 2016;11(4):89–104.
[38] Bakare EA, Nwagwo A, Danso-Addo E. Optimal control analysis of a SIR epidemic model with constant recruitment. Int J Appl Math Res. 2014;3(3):273–85.
[39] Zakary O, Rachik M, Elmouki I. On the analysis of a multi-regions discrete SIR epidemic model: an optimal control approach. Int J Dyn Control. 2017;5(3):917–30. doi:10.1007/s40435-016-0233-2.
[40] Lenhart S, Workman JT. Optimal Control Applied to Biological Models. Chapman & Hall/CRC, Boca Raton; 2007.
[41] Goodfellow I, Bengio Y, Courville A. Deep Learning. MIT Press, Cambridge, MA; 2016.
[42] Sutton RS, Barto AG. Reinforcement Learning: An Introduction. MIT Press, Cambridge, MA; 2018.
[43] LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015;521(7553):436–44.
[44] Silver D, Huang A, Maddison CJ, Guez A, Sifre L, van den Driessche G, et al. Mastering the game of Go with deep neural networks and tree search. Nature. 2016;529(7587):484–89.
[45] Chayoukh O, Zakary O. Application of artificial intelligence to control a nonlinear SIR model. In: Chakir A, Andry JF, Ullah A, Bansal R, Ghazouani M, eds. Engineering Applications of Artificial Intelligence. Springer, Cham; 2024. p. 23–39. doi:10.1007/978-3-031-50300-9_2.
[46] Hattaf K, Lashari A, Louartassi Y, Yousfi N. A delayed SIR epidemic model with a general incidence rate. Electron J Qual Theory Differ Equ. 2013;2013(3):1–9.
[47] Jing W, Jin Z, Zhang J. An SIR pairwise epidemic model with infection age and demography. J Biol Dyn. 2018;12(1):486–508.
[48] AlQadi H, Bani-Yaghoub M. Incorporating global dynamics to improve the accuracy of disease models: example of a COVID-19 SIR model. PLoS One. 2022;17(4):e0265815.
[49] Wang H, Wu D, Luo J, Zhang J. Integrating socio-psychological factors in the SEIR model optimized by a genetic algorithm for COVID-19 trend analysis. Sci Rep. 2024;14:15684.
[50] Sun T, Jin B, Wu Y, Bao J. A study of the attenuation stage of a global infectious disease. Front Public Health. 2024;12:1379481.
[51] Zakary O, Bidah S, Rachik M. Optimizing infection trajectories: innovation in controllability of nonlinear SIR model. Rev Mex Ing Biomed. 2024;45(2):151–71.